Anthony M Allison

US Patent:

6962903, Nov 8, 2005

Filed:

Feb 21, 2002

Appl. No.:

10/080370

Inventors:

Anthony Allison - Belmont CA, US

Assignee:

Alavita, Inc. - Menlo Park CA

International Classification:

A61K038/17
C08L089/00
C07K014/435

US Classification:

514 12, 530350, 525 541, 435 6

Abstract:

A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.

US Patent:

6982154, Jan 3, 2006

Filed:

Aug 1, 2003

Appl. No.:

10/632694

Inventors:

Anthony Allison - Belmont CA, US

Assignee:

Surromed, Inc. - Menlo Park CA

International Classification:

A61K 38/17
A61K 39/395
C12P 21/06

US Classification:

435 691, 4241781, 514 12

Abstract:

Sickle-cell diseases are treated with annexin proteins that are modified to increase their half-life in the circulation.

US Patent:

7407475, Aug 5, 2008

Filed:

Apr 20, 2005

Appl. No.:

11/110306

Inventors:

Anthony Allison - Belmont CA, US

Assignee:

Alavita Pharmaceuticals, Inc. - Mountainview CA

International Classification:

A61K 38/00

US Classification:

500300, 500350

Abstract:

A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.

US Patent:

7635676, Dec 22, 2009

Filed:

Nov 3, 2005

Appl. No.:

11/267837

Inventors:

Anthony Allison - Belmont CA, US

Assignee:

Alavita Pharmaccuticals, Inc. - Mountain View CA

International Classification:

A61K 38/17

US Classification:

514 12, 514 2, 530350, 530300, 435 71

Abstract:

Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage.

US Patent:

7635678, Dec 22, 2009

Filed:

Sep 14, 2006

Appl. No.:

11/520985

Inventors:

Anthony Allison - Belmont CA, US

Assignee:

Alavita Pharmaceuticals, Inc. - Mountain View CA

International Classification:

A61K 38/17

US Classification:

514 12, 514 2, 530350, 530300

Abstract:

Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage.

US Patent:

7635680, Dec 22, 2009

Filed:

Apr 12, 2007

Appl. No.:

11/734471

Inventors:

Anthony Allison - Belmont CA, US

Assignee:

Alavita Pharmaceuticals, Inc. - Mountain View CA

International Classification:

A61K 38/17

US Classification:

514 12, 514 2, 530350, 530300, 435 71

Abstract:

Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothrombinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage. In addition, the modified annexin prevents lipid loss from platelets during storage.

US Patent:

7645739, Jan 12, 2010

Filed:

Jul 14, 2006

Appl. No.:

11/486667

Inventors:

Anthony Clifford Allison - Belmont CA, US

Assignee:

Alavita Pharmaceuticals, Inc. - Mountain View CA

International Classification:

A61K 38/17

US Classification:

514 12, 514 2, 514 13, 435 71

Abstract:

Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage. In addition, the modified annexin prevents lipid loss from platelets during storage.

US Patent:

20020016372, Feb 7, 2002

Filed:

Jun 11, 2001

Appl. No.:

09/879498

Inventors:

Anthony Allison - Belmont CA, US

International Classification:

A61K031/122

US Classification:

514/682000

Abstract:

A method for preventing and treating AD is supplementation with vitamin K so that the concentration of the vitamin in the circulation is sufficient for its functions outside the liver. Vitamin K supplementation will also be useful to reduce brain damage associated with cardiovascular disease and injury. Vitamin K can be administered orally, subcutaneously, intramuscularly or intravenously. The vitamin K can be phylloquinone, menaquinones of varying chain lengths, or menadione. Preferred forms of the vitamin are all-trans menadione and menaquinone-4. These are formulated so as to ensure efficient absorption from the gastrointestinal tract and rapid bioavailability in the brain following administration.